Targeted Lymphoablation as an alternative to HSCT to cure T1D
Increase in obesity, unhealthy diet, and physical inactivity are driving the prevalence of diabetes among all ages. In the U.S., diabetes currently affects 14% of the population of all ages, and it is the seventh leading cause of death, with an estimated cost of $237 billion every year to the healthcare system. With insulin being the only approved treatment of Type 1 diabetes mellitus (T1DM), there is a very large unmet medical need for a definitive cure for pediatric and adult patients.
The medical community has recognized diabetes as an autoimmune disease and proposed different immunotherapeutic approaches to cure it. However, only hematopoietic stem cell transplantation (HSCT) after reset of the immune system with toxic chemotherapy, has so far shown temporary restoration of insulin independence.
The mission of AVM Biotechnology is to develop a disruptive solution for diabetes based on a novel regimen for immunologic reset that safely removes the complete autoimmune pathophysiologic substrates from diabetes patients and can be safely re-administered in case of relapse.